OC
FBIO icon

Oppenheimer & Co’s Fortress Biotech FBIO Stock Holding History

Oppenheimer & Co’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-789
Closed -$83K – 1410
2013
Q3 		$83K Buy
789
+92
+13% +$11.3K ﹤0.01% 1255
2013
Q2 		$90K Buy
+697
New +$103K ﹤0.01% 1197

Other funds holding FBIO

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $8.8B AUM 29.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Oppenheimer & Co's FBIO Position: Q4 2013 in Review

Oppenheimer & Co sold out of Fortress Biotech (FBIO) in Q4 2013, closing a stake of 789 shares — an estimated $83K sold.

Oppenheimer & Co first reported a position in FBIO in Q2 2013 and held it in 2 quarters. The position peaked at $90K in Q2 2013. 60 funds tracked by Wall St. Rank hold FBIO as of Q4 2013.

  • Oppenheimer & Co reported no remaining Fortress Biotech position as of Q4 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 789 Fortress Biotech shares in Q4 2013, an estimated $83K.
  • Oppenheimer & Co first reported a position in Fortress Biotech in Q2 2013 and held it in 2 quarters.
  • Oppenheimer & Co's Fortress Biotech position peaked at $90K in Q2 2013.
  • 60 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2013.

Based on Oppenheimer & Co's 13F filing for Q4 2013, filed 12 Feb 2014.